Ask AI
ProCE Banner Activity

HER2: Biology, Testing, and ADC-Based Treatment in Gastrointestinal, Genitourinary, and Gynecologic Malignancies

Clinical Thought

This expert commentary from Zev A. Wainberg, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explores testing for HER2 alterations and the optimal use of HER2-targeted ADCs in gastrointestinal, genitourinary, and gynecologic malignancies.

Released: August 25, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.

Disclosure

Primary Author

Catherine Fahey, MD, PhD, has no relevant financial relationships to disclose.

Alexandra Leary, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Daiichi Sankyo, Genmab, GlaxoSmithKline, ImmunoGen, Merck Sharp & Dohme, Pharm&, Zentalis; researcher: AstraZeneca, Zentalis.

Zev A. Wainberg, MD: consultant/advisor/speaker: Alligator, Amgen, Arcus, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Ipsen, Janssen, Jazz, Lilly, Merck, Novartis, Pfizer.